Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

mediaphotos/iStock via Getty Images

• Dr. Reddy's Laboratories said its unit Aurigene, and EQRx are collaborating to develop drug candidates for cancer and immune-inflammatory diseases.
• Under the agreement, Aurigene will use its small molecule drug discovery platform and will lead drug discovery and pre-clinical development efforts while EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
• The companies said they would share funding on development and any commercialization of potential drug candidates.